CP 471474

Key Product Details

Product Description

CP 471474 is a broad spectrum MMP inhibitor (IC₅₀ values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). Attenuates early left ventricular dilation after experimental myocardial infarction in mice.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Product Specifications for CP 471474

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CP 471474

The following data is based on the product molecular weight 368.38.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.71 mL	13.57 mL	27.15 mL
5 mM	0.54 mL	2.71 mL	5.43 mL
10 mM	0.27 mL	1.36 mL	2.71 mL
50 mM	0.05 mL	0.27 mL	0.54 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Lindsey Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002 PMID: 11839633
• Fang Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J.Mol.Cell.Cardiol. 2007 PMID: 17689559
• Rohde Matrix metalloproteinease inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999 PMID: 10368126

Product Documents for CP 471474